Please sign in to follow a disease.
Relapsed/refractory B-cell lymphoma
Clinical trials for Relapsed/refractory B-cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory B-cell lymphoma trials appear
Sign up with your email to follow new studies for Relapsed/refractory B-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental 'Off-the-Shelf' CAR-T therapy takes on tough lymphoma
Disease control Not yet recruitingThis early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to other treatments. RN1701 is a type of immune cell therapy made from donor cells, designed to target two markers on cancer cells. The study will enroll…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Early phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Nanobody-Powered CAR-Ts take on tough lymphoma
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy that uses tiny antibodies (nanobodies) to target two markers on cancer cells (CD19 and CD20). The goal is to see if it is safe and to find the best dose for people with B-cell lymphoma that has come back or not respond…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Early phase 1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New CAR-T therapy takes aim at tough lymphoma cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CY-219 CAR-T cells in 18 people whose B-cell lymphoma has come back or stopped responding to standard care. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are …
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New CAR-T therapy aims to tackle tough lymphoma
Disease control Not yet recruitingThis early study is testing a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard treatments. RN1701 is a type of immunotherapy made from donor cells (allogeneic CAR-T) that targets two proteins on cancer cells. The main goa…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase 1/2 • Sponsor: Affiliated Hospital of Nantong University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Simpler CAR-T therapy tested for tough blood cancers
Disease control Not yet recruitingThis early study tests a new CAR-T cell therapy that is made inside the body, avoiding the complex and costly lab process. It targets two proteins (CD19 and BAFF-R) on cancer cells in people with relapsed or hard-to-treat B-cell leukemia or lymphoma. The main goals are to check s…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase 1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New CAR-T therapy aims to fight hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard therapy. RN1701 uses specially engineered immune cells from a donor to target and kill cancer cells. The main goals are to check safety and s…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase 1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC